nach oben

Head and Neck Pathology

Erschienen in:

16.03.2023 | Special Issue: Top Ten Head and Neck Differentials

Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies

verfasst von: Martin D. Hyrcza, Tanya R. Lindenmuth, Aaron Auerbach

Erschienen in: Head and Neck Pathology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Oral ulcers represent a full thickness loss of the mucosal epithelium leading to exposure of the submucosal connective tissue. These are common and usually self-limited lesions, although they may sometimes result from neoplasms, most commonly squamous cell carcinoma. Lymphoproliferative disorders may be difficult to diagnose in apthous ulcers since they mimic reactive inflammation.

Methods

This review presents ten rare oral lymphoid proliferations which should not be missed when assessing oral ulcer biopsies.

Results

The ten lesions include several with diagnostic cells which look similar to the histiocytes of a reactive inflammatory ulcer, including Rosai–Dorfman disease, reticulohistiocytoma, Langerhans cell histiocytosis, and traumatic ulcerative granuloma. Other lesions, such as EBV-positive mucocutaneous ulcer, extranodal marginal zone lymphoma of mucosal-associated lymphoid tissue, and plasmablastic lymphoma have lymphoid and/or plasma cell differentiation that mimic the reactive lymphocytes and plasma cells found in reactive ulcers. Two dendritic cell lesions, follicular dendritic cell sarcoma and blastic plasmacytoid dendritic cell neoplasm, both have distinct phenotypes which are required to make an accurate diagnosis.

Conclusion

Each of these lesions are diagnosed by evaluating their histology, along with their phenotypic profile, which is sometimes enhanced by pertinent molecular findings.

Cebeci AR, Gülşahi A, Kamburoglu K, Orhan BK, Oztaş B (2009) Prevalence and distribution of oral mucosal lesions in an adult Turkish population. Med Oral Patol Oral Cir Bucal 14(6):E272–E277PubMed

Fitzpatrick SG, Cohen DM, Clark AN (2019) Ulcerated lesions of the oral mucosa: clinical and histologic review. Head Neck Pathol 13(1):91–102. https://doi.org/10.1007/s12105-018-0981-8CrossRefPubMedPubMedCentral

Compilato D, Cirillo N, Termine N, Kerr AR, Paderni C, Ciavarella D et al (2009) Long-standing oral ulcers: proposal for a new “S-C-D classification system.” J Oral Pathol Med 38(3):241–253. https://doi.org/10.1111/j.1600-0714.2008.00722.xCrossRefPubMed

Allon I, Allon DM, Anavi Y, Kaplan I (2013) The significance of surface ulceration as a sign of malignancy in exophytic oral mucosal lesions: myth or fact? Head Neck Pathol 7(2):149–154. https://doi.org/10.1007/s12105-012-0413-0CrossRefPubMed

Destombes P (1965) Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali (4 cases). Bull Soc Pathol Exot Filiales 58(6):1169–1175PubMed

Rosai J, Dorfman RF (1969) Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 87(1):63–70PubMed

Kiruthiga KG, Younes S, Natkunam Y (2022) Strong coexpression of transcription factors PU.1 and Oct-2 in Rosai-Dorfman disease. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqac119CrossRefPubMed

Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J et al (2017) Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 30(10):1367–1377. https://doi.org/10.1038/modpathol.2017.55CrossRefPubMedPubMedCentral

Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A (2016) Rosai-Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol 10(3):394–399. https://doi.org/10.1007/s12105-016-0709-6CrossRefPubMedPubMedCentral

10.

Goodnight JW, Wang MB, Sercarz JA, Fu YS (1996) Extranodal Rosai-Dorfman disease of the head and neck. Laryngoscope 106(3 Pt 1):253–256. https://doi.org/10.1097/00005537-199603000-00002CrossRefPubMed

11.

Silver AL, Farkash EA, Pitman MB, Rocco JW (2011) Rosai-Dorfman disease presenting in the oropharynx. Head Neck 33(11):1660–1663. https://doi.org/10.1002/hed.21446CrossRefPubMed

12.

Illing EA, Halum SL (2012) Rosai-Dorfman disease with isolated laryngeal involvement. Ear Nose Throat J 91(10):439–440CrossRefPubMed

13.

Di Dier K, Lemmerling M, De Vos G (2022) Nasal and nasopharyngeal Rosai-Dorfman disease. J Belg Soc Radiol 106(1):86. https://doi.org/10.5334/jbsr.2896CrossRefPubMedPubMedCentral

14.

Ojha J, Rawal YB, Hornick JL, Magliocca K, Montgomery DR, Foss RD et al (2020) Extra nodal Rosai-Dorfman disease originating in the nasal and paranasal complex and gnathic bones: a systematic analysis of seven cases and review of literature. Head Neck Pathol 14(2):442–453. https://doi.org/10.1007/s12105-019-01056-8CrossRefPubMed

15.

Cardoso CL, Damante JH, Santos PS, Taveira LA, Fernandes LM, Pigatti FM et al (2012) Rosai-Dorfman disease with widespread oral-maxillofacial manifestations: a case report. J Oral Maxillofac Surg 70(11):2600–2604. https://doi.org/10.1016/j.joms.2011.12.015CrossRefPubMed

16.

Alawi F, Robinson BT, Carrasco L (2006) Rosai-Dorfman disease of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102(4):506–512. https://doi.org/10.1016/j.tripleo.2005.10.071CrossRefPubMed

17.

Kademani D, Patel SG, Prasad ML, Huvos AG, Shah JP (2002) Intraoral presentation of Rosai-Dorfman disease: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93(6):699–704. https://doi.org/10.1067/moe.2002.123495CrossRefPubMed

18.

Keskin A, Genç F, Günhan O (2007) Rosai-Dorfman disease involving maxilla: a case report. J Oral Maxillofac Surg 65(12):2563–2568. https://doi.org/10.1016/j.joms.2006.10.003CrossRefPubMed

19.

Jacobsen E, Shanmugam V, Jagannathan J (2017) Rosai-Dorfman disease with activating KRAS mutation - response to cobimetinib. N Engl J Med 377(24):2398–2399. https://doi.org/10.1056/NEJMc1713676CrossRefPubMed

20.

Zak FG (1950) Reticulohistiocytoma (“ganglioneuroma”) of the skin. Br J Dermatol Syph 62(9):351–355. https://doi.org/10.1111/j.1365-2133.1950.tb15475.xCrossRefPubMed

21.

Miettinen M, Fetsch JF (2006) Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases. Am J Surg Pathol 30(4):521–528. https://doi.org/10.1097/00000478-200604000-00014CrossRefPubMed

22.

Hoyt BS, Yan S, Linos KD, Momtahen S, Sriharan A, Tran TN et al (2019) BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: testing may be useful in screening for Erdheim-Chester disease. Exp Mol Pathol 111:104320. https://doi.org/10.1016/j.yexmp.2019.104320CrossRefPubMed

23.

Bahrani E, Fernandez-Pol S, Wang JY, Aasi SZ, Brown RA, Novoa RA (2020) Reticulohistiocytoma (solitary epithelioid histiocytoma) with mutations in RAF1 and TSC2. J Cutan Patho 47:985–987CrossRef

24.

Agarwala S, Hafeez F (2021) Letter to editor: characterizing the lack of specificity of the histopathological findings seen in multicentric reticulohistiocytosis and reticulohistiocytoma. Ann Clin Lab Sci 51(6):894–895PubMed

25.

Selmi C, Greenspan A, Huntley A, Gershwin ME (2015) Multicentric reticulohistiocytosis: a critical review. Curr Rheumatol Rep 17(6):511. https://doi.org/10.1007/s11926-015-0511-6CrossRefPubMed

26.

Yoshimura Y, Sugihara T, Kishimoto H, Nagaoka S (1987) Multicentric reticulohistiocytosis accompanied by oral and temporomandibular joint manifestations. J Oral Maxillofac Surg 45(1):84–86. https://doi.org/10.1016/0278-2391(87)90094-2CrossRefPubMed

27.

Katz RW, Anderson KF (1988) Multicentric reticulohistiocytosis. Oral Surg Oral Med Oral Pathol 65(6):721–725. https://doi.org/10.1016/0030-4220(88)90017-5CrossRefPubMed

28.

Monda L, Warnke R, Rosai J (1986) A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am J Pathol 122(3):562–572PubMedPubMedCentral

29.

Chan JK, Tsang WY, Ng CS, Tang SK, Yu HC, Lee AW (1994) Follicular dendritic cell tumors of the oral cavity. Am J Surg Pathol 18(2):148–157. https://doi.org/10.1097/00000478-199402000-00004CrossRefPubMed

30.

Biddle DA, Ro JY, Yoon GS, Yong Y-WH, Ayala AG, Ordonez NG (2002) Extranodal follicular dendritic cell sarcoma of the head and neck region: three new cases, with a review of the literature. Mod Pathol 15(1):50–58. https://doi.org/10.1038/modpathol.3880489CrossRefPubMed

31.

Li J, Zhou ML, Zhou SH (2015) Clinical and pathological features of head and neck follicular dendritic cell sarcoma. Hematology 20(10):571–583. https://doi.org/10.1179/1607845415y.0000000008CrossRefPubMed

32.

Pang J, Mydlarz WK, Gooi Z, Waters KM, Bishop J, Sciubba JJ et al (2016) Follicular dendritic cell sarcoma of the head and neck: Case report, literature review, and pooled analysis of 97 cases. Head Neck 38(Suppl 1):E2241–E2249. https://doi.org/10.1002/hed.24115CrossRefPubMed

33.

Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N (2013) Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol 88(2):253–271. https://doi.org/10.1016/j.critrevonc.2013.05.006CrossRefPubMed

34.

Duan GJ, Wu F, Zhu J, Guo DY, Zhang R, Shen LL et al (2010) Extranodal follicular dendritic cell sarcoma of the pharyngeal region: a potential diagnostic pitfall, with literature review. Am J Clin Pathol 133(1):49–58. https://doi.org/10.1309/ajcp7u8yisbuavnwCrossRefPubMed

35.

Hu T, Wang X, Yu C, Yan J, Zhang X, Li L et al (2013) Follicular dendritic cell sarcoma of the pharyngeal region. Oncol Lett 5(5):1467–1476. https://doi.org/10.3892/ol.2013.1224CrossRefPubMedPubMedCentral

36.

Martins MT, Witzel AL, Sugaya NN, Kowalski LP, de Araujo VC (2004) Dendritic cell sarcoma of the oral cavity. Oral Oncol 40(3):341–347. https://doi.org/10.1016/j.oraloncology.2003.08.012CrossRefPubMed

37.

Facchetti F, Lorenzi L (2016) Follicular dendritic cells and related sarcoma. Semin Diagn Pathol 33(5):262–276. https://doi.org/10.1053/j.semdp.2016.05.002CrossRefPubMed

38.

Massoth LR, Hung YP, Ferry JA, Hasserjian RP, Nardi V, Nielsen GP et al (2021) Histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma. Oncologist 26(7):e1263–e1272. https://doi.org/10.1002/onco.13801CrossRefPubMedPubMedCentral

39.

Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ et al (2014) Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 65(2):261–272. https://doi.org/10.1111/his.12416CrossRefPubMed

40.

Allen CE, Merad M, McClain KL (2018) Langerhans-cell histiocytosis. N Engl J Med 379(9):856–868. https://doi.org/10.1056/NEJMra1607548CrossRefPubMedPubMedCentral

41.

Bagnasco F, Zimmermann SY, Egeler RM, Nanduri VR, Cammarata B, Donadieu J et al (2022) Langerhans cell histiocytosis and associated malignancies: a retrospective analysis of 270 patients. Eur J Cancer 172:138–145. https://doi.org/10.1016/j.ejca.2022.03.036CrossRefPubMed

42.

Faustino ISP, Fernandes PM, Pontes HAR, Mosqueda-Taylor A, Santos-Silva AR, Vargas PA et al (2021) Langerhans cell histiocytosis in the oral and maxillofacial region: an update. J Oral Pathol Med 50(6):565–571. https://doi.org/10.1111/jop.13207CrossRefPubMed

43.

Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H et al (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007–3015. https://doi.org/10.1182/blood-2014-05-577825CrossRefPubMedPubMedCentral

44.

AbdullGaffar B, Awadhi F (2020) Oral manifestations of langerhans cell histiocytosis with unusual histomorphologic features. Ann Diagn Pathol 47:151536. https://doi.org/10.1016/j.anndiagpath.2020.151536CrossRefPubMed

45.

Neves-Silva R, Fernandes DT, Fonseca FP, Rebelo Pontes HA, Brasileiro BF, Santos-Silva AR et al (2018) Oral manifestations of langerhans cell histiocytosis: a case series. Spec Care Dentist 38(6):426–433. https://doi.org/10.1111/scd.12330CrossRefPubMed

46.

Bedran NR, Carlos R, de Andrade BAB, Bueno APS, Romañach MJ, Milito CB (2018) Clinicopathological and immunohistochemical study of head and neck langerhans cell histiocytosis from Latin America. Head Neck Pathol 12(4):431–439. https://doi.org/10.1007/s12105-017-0867-1CrossRefPubMed

47.

Howard JE, Masterson L, Dwivedi RC, Jani P (2016) Langerhans cell sarcoma of the head and neck. Crit Rev Oncol Hematol 99:180–188. https://doi.org/10.1016/j.critrevonc.2015.12.017CrossRefPubMed

48.

Salisbury CL, Budnick SD, Li S (2009) T-cell receptor gene rearrangement and CD30 immunoreactivity in traumatic ulcerative granuloma with stromal eosinophilia of the oral cavity. Am J Clin Pathol 132(5):722–727. https://doi.org/10.1309/ajcpx3s5msovvlopCrossRefPubMed

49.

Hirshberg A, Amariglio N, Akrish S, Yahalom R, Rosenbaum H, Okon E et al (2006) Traumatic ulcerative granuloma with stromal eosinophilia: a reactive lesion of the oral mucosa. Am J Clin Pathol 126(4):522–529. https://doi.org/10.1309/afha406gbt0n2y64CrossRefPubMed

50.

Aizic A, Raiser V, Solar I, Aharon Z, Shlomi B, Kaplan I (2019) Traumatic ulcerative granuloma with stromal eosinophilia: CD30 analysis and clonality for T cell receptor gene re-arrangement. Acta Histochem 121(8):151450. https://doi.org/10.1016/j.acthis.2019.151450CrossRefPubMed

51.

Alobeid B, Pan LX, Milligan L, Budel L, Frizzera G (2004) Eosinophil-rich CD30+ lymphoproliferative disorder of the oral mucosa. A form of “traumatic eosinophilic granuloma.” Am J Clin Pathol 121(1):43–50. https://doi.org/10.1309/jqfx-pnd6-dblf-6b9uCrossRefPubMed

52.

Agarwal M, Shenjere P, Blewitt RW, Hall G, Sloan P, Pigadas N et al (2008) CD30-positive T-cell lymphoproliferative disorder of the oral mucosa–an indolent lesion: report of 4 cases. Int J Surg Pathol 16(3):286–290. https://doi.org/10.1177/1066896907313755CrossRefPubMed

53.

Rosenberg A, Blesma DH, Sie-Go DMDS, Slootweg PJ (1996) Primary extranodal CD30-positive T-cell non-Hodgkin’s lymphoma of the oral mucosa: report of two cases. Int J Oral Maxillofac Surg 25(1):57–59. https://doi.org/10.1016/S0901-5027(96)80013-0CrossRefPubMed

54.

Sciallis AP, Law ME, Inwards DJ, McClure RF, Macon WR, Kurtin PJ et al (2012) Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. Mod Pathol 25(7):983–992. https://doi.org/10.1038/modpathol.2012.38CrossRefPubMed

55.

Wang W, Cai Y, Sheng W, Lu H, Li X (2014) The spectrum of primary mucosal CD30-positive T-cell lymphoproliferative disorders of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol 117(1):96–104. https://doi.org/10.1016/j.oooo.2013.10.002CrossRefPubMed

56.

WHO Classification of tumours of haematopoietic and lymphoid tissues (2017). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, (eds) Revised 4th edn, vol 2

57.

Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES (2010) EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 34(3):405–417. https://doi.org/10.1097/PAS.0b013e3181cf8622CrossRefPubMedPubMedCentral

58.

Castro Limo JD, Sierra Bernal CA, Martínez ZE (2021) Epstein-Barr virus-positive mucocutaneous ulcer mimicking sigmoid colon adenocarcinoma. Rev Esp Enferm Dig 113(3):225–226. https://doi.org/10.17235/reed.2020.7272/2020CrossRefPubMed

59.

Prieto-Torres L, Eraña I, Gil-Redondo R, Gómez de la Riva I, Manso R, Pajares R et al (2019) The spectrum of EBV-positive mucocutaneous ulcer: a study of 9 cases. Am J Surg Pathol 43(2):201–210. https://doi.org/10.1097/pas.0000000000001186CrossRefPubMed

60.

Ikeda T, Gion Y, Sakamoto M, Tachibana T, Nishikori A, Nishimura MF et al (2020) Clinicopathological analysis of 34 Japanese patients with EBV-positive mucocutaneous ulcer. Mod Pathol 33(12):2437–2448. https://doi.org/10.1038/s41379-020-0599-8CrossRefPubMed

61.

Attard AA, Praveen P, Dunn PJ, James GJ (2012) Epstein-Barr virus-positive mucocutaneous ulcer of the oral cavity: the importance of having a detailed clinical history to reach a correct diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol 114(2):e37–e39. https://doi.org/10.1016/j.oooo.2012.04.003CrossRefPubMed

62.

Natkunam Y, Goodlad JR, Chadburn A, de Jong D, Gratzinger D, Chan JK et al (2017) EBV-positive B-cell proliferations of varied malignant potential: 2015 SH/EAHP workshop report-part 1. Am J Clin Pathol 147(2):129–152. https://doi.org/10.1093/ajcp/aqw214CrossRefPubMedPubMedCentral

63.

Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE et al (1981) Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 48(6):1426–1437. https://doi.org/10.1002/1097-0142(19810915)48:6%3c1426::aid-cncr2820480626%3e3.0.co;2-gCrossRefPubMed

64.

Zhou J, Bell D, Medeiros LJ (2013) Myeloid sarcoma of the head and neck region. Arch Pathol Lab Med 137(11):1560–1568. https://doi.org/10.5858/arpa.2012-0537-OACrossRefPubMed

65.

Pau M, Beham-Schmid C, Zemann W, Kahr H, Kärcher H (2010) Intraoral granulocytic sarcoma: a case report and review of the literature. J Oral Maxillofac Surg 68(10):2569–2574. https://doi.org/10.1016/j.joms.2009.09.040CrossRefPubMed

66.

Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M et al (2021) Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):3402–3410. https://doi.org/10.1080/10428194.2021.1961235CrossRefPubMedPubMedCentral

67.

Papamanthos MK, Kolokotronis AE, Skulakis HE, Fericean AM, Zorba MT, Matiakis AT (2010) Acute myeloid leukaemia diagnosed by intra-oral myeloid sarcoma. A case report Head Neck Pathol 4(2):132–135. https://doi.org/10.1007/s12105-010-0163-9CrossRefPubMed

68.

Xie Z, Zhang F, Song E, Ge W, Zhu F, Ja Hu (2007) Intraoral granulocytic sarcoma presenting as multiple maxillary and mandibular masses: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103(6):e44–e48. https://doi.org/10.1016/j.tripleo.2006.12.028CrossRefPubMed

69.

Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M et al (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21(2):340–350. https://doi.org/10.1038/sj.leu.2404491CrossRefPubMed

70.

Wilson CS, Medeiros LJ (2015) Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol 144(2):219–239. https://doi.org/10.1309/ajcpo58ywibubesxCrossRefPubMed

71.

Amador-Ortiz C, Hurley M, Ghahramani G, Frisch S, Klco J, Lind A et al (2011) Use of classic and novel immunohistochemical markers in the diagnosis of cutaneous myeloid sarcoma. J Cutan Pathol 38:945–953. https://doi.org/10.1111/j.1600-0560.2011.01809.xCrossRefPubMed

72.

Roth MJ, Medeiros LJ, Elenitoba-Johnson K, Kuchnio M, Jaffe ES, Stetler-Stevenson M (1995) Extramedullary myeloid cell tumors. An immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. Arch Pathol Lab Med 119(9):790–798PubMed

73.

Zhou T, Bloomquist MS, Ferguson LS, Reuther J, Marcogliese AN, Elghetany MT et al (2020) Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis. Pediatr Hematol Oncol 37(1):76–89. https://doi.org/10.1080/08880018.2019.1683107CrossRefPubMed

74.

Begna KH, Kittur J, Yui J, Gangat N, Patnaik MM, Al-Kali A et al (2021) De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol 195(3):413–416. https://doi.org/10.1111/bjh.17742CrossRefPubMed

75.

Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O’Brien S, Brandt M et al (2008) Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 113(6):1370–1378. https://doi.org/10.1002/cncr.23691CrossRefPubMed

76.

Li Y, Sun V, Sun W, Pawlowska A (2020) Blastic plasmacytoid dendritic cell neoplasm in children. Hematol Oncol Clin North Am 34(3):601–612. https://doi.org/10.1016/j.hoc.2020.01.008CrossRefPubMed

77.

Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L et al (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169(3):579–586. https://doi.org/10.1111/bjd.12412CrossRefPubMed

78.

Hashikawa K, Niino D, Yasumoto S, Nakama T, Kiyasu J, Sato K et al (2012) Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm. J Am Acad Dermatol 66(2):278–291. https://doi.org/10.1016/j.jaad.2010.12.043CrossRefPubMed

79.

Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S et al (2021) Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood 138(15):1373–1377. https://doi.org/10.1182/blood.2021011817CrossRefPubMed

80.

Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S et al (2022) Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343–1350. https://doi.org/10.1038/s41375-022-01538-9CrossRefPubMed

81.

Khoury JD (2018) Blastic plasmacytoid dendritic cell neoplasm. Curr Hematol Malig Rep 13(6):477–483. https://doi.org/10.1007/s11899-018-0489-zCrossRefPubMed

82.

Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28(8):1606–1616. https://doi.org/10.1038/leu.2014.64CrossRefPubMedPubMedCentral

83.

Feuillard J, Jacob M-C, Valensi F, Maynadié M, Gressin R, Chaperot L et al (2002) Clinical and biologic features of CD4+CD56+ malignancies. Blood 99(5):1556–1563. https://doi.org/10.1182/blood.V99.5.1556CrossRefPubMed

84.

Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101(12):5007–5009. https://doi.org/10.1182/blood-2002-10-3297CrossRefPubMed

85.

Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA et al (2019) Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol 43(10):1429–1437. https://doi.org/10.1097/pas.0000000000001316CrossRef

86.

Marafioti T, Paterson JC, Ballabio E, Reichard KK, Tedoldi S, Hollowood K et al (2008) Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 111(7):3778–3792. https://doi.org/10.1182/blood-2007-10-117531CrossRefPubMed

87.

Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S et al (2021) Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 106(4):1047–1055CrossRefPubMed

88.

Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE et al (2016) Simultaneous deletion of 3’ETV6 and 5’EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet 9:23. https://doi.org/10.1186/s13039-016-0232-1CrossRefPubMedPubMedCentral

89.

Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H et al (2018) Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia 32(12):2590–2603. https://doi.org/10.1038/s41375-018-0154-5CrossRefPubMed

90.

Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M et al (2019) Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica 104(4):729–737. https://doi.org/10.3324/haematol.2018.202093CrossRefPubMedPubMedCentral

91.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W et al (2019) Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 380(17):1628–1637. https://doi.org/10.1056/NEJMoa1815105CrossRefPubMed

92.

Corti M, Minué G, Campitelli A, Narbaitz M, Gilardi L (2015) An aggressive plasmablastic lymphoma of the oral cavity as primary manifestation of acquired immunodeficiency syndrome: case report and literature review. Int Arch Otorhinolaryngol. 19(4):354–358. https://doi.org/10.1055/s-0034-1397335CrossRefPubMedPubMedCentral

93.

Vale DAD, Rogado CM, Carvalho DLC, Trierveiler M, Ortega KL (2017) Oral plasmablastic lymphoma as the first manifestation of AIDS. An Bras Dermatol 92(5 Suppl 1):110–112. https://doi.org/10.1590/abd1806-4841.20175417CrossRefPubMedPubMedCentral

94.

Zizzo M, Zanelli M, Martiniani R, Sanguedolce F, De Marco L, Martino G et al (2020) Oral plasmablastic lymphoma: a case report. Medicine (Baltimore) 99(39):e22335. https://doi.org/10.1097/md.0000000000022335CrossRefPubMed

95.

Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh ER, Opie JJ (2022) Plasmablastic lymphoma: an update. Int J Lab Hematol 44(Suppl 1):54–63. https://doi.org/10.1111/ijlh.13863CrossRefPubMedPubMedCentral

96.

Lin L, Zhang X, Dong M, Li L, Wang X, Zhang L et al (2017) Human immunodeficiency virus-negative plasmablastic lymphoma: a case report and literature review. Medicine (Baltimore) 96(7):e6171. https://doi.org/10.1097/md.0000000000006171CrossRefPubMed

97.

Bagul N, Mamatha GS, Mahalle A (2012) Plasmablastic lymphoma of gingiva mimicking a reactive lesion: a case report. Case Rep Dent 2012:259307. https://doi.org/10.1155/2012/259307CrossRefPubMedPubMedCentral

98.

Hansra D, Montague N, Stefanovic A, Akunyili I, Harzand A, Natkunam Y et al (2010) Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol 134(5):710–719. https://doi.org/10.1309/ajcpjh6keusecqluCrossRefPubMed

99.

Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C et al (2015) Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases. Oncol Rep 33(4):1615–1620. https://doi.org/10.3892/or.2015.3808CrossRefPubMedPubMedCentral

100.

Yonal-Hindilerden I, Hindilerden F, Arslan S, Turan-Guzel N, Dogan IO, Nalcaci M (2016) Primary B-cell mucosa-associated lymphoid tissue lymphoma of the hard palate and parotid gland: report of one case and review of the literature. J Clin Med Res 8(11):824–830. https://doi.org/10.14740/jocmr2733wCrossRefPubMedPubMedCentral

101.

Iversen L, Eriksen PRG, Andreasen S, Clasen-Linde E, Homøe P, Wessel I et al (2021) Lymphoma of the uvula: clinical, morphological, histopathological, and genetic characterization. A nationwide Danish study from 1980 to 2019. Front Surg 8:675279. https://doi.org/10.3389/fsurg.2021.675279CrossRefPubMedPubMedCentral

102.

Ma S, Jug R, Shen S, Zhang WL, Xu HT, Yang LH (2018) Marginal zone lymphoma of palatine tonsil with prominent plasmacytic differentiation: A CARE-compliant article and review of literature. Medicine (Baltimore) 97(2):e9648. https://doi.org/10.1097/md.0000000000009648CrossRefPubMed

103.

Khalil MO, Morton LM, Devesa SS, Check DP, Curtis RE, Weisenburger DD et al (2014) Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site. Br J Haematol 165(1):67–77. https://doi.org/10.1111/bjh.12730CrossRefPubMedPubMedCentral

104.

Tanaka T, Kitabatake K, Iino M, Goto K (2011) Immunohistochemical comparison of CD5, lambda, and kappa expression in primary and recurrent buccal mucosa-associated lymphoid tissue (MALT) lymphomas. Diagn Pathol 6:82. https://doi.org/10.1186/1746-1596-6-82CrossRefPubMedPubMedCentral

105.

Alderuccio JP, Florindez JA, Reis IM, Zhao W, Lossos IS (2021) Treatments and outcomes in stage I extranodal marginal zone lymphoma in the United States. Cancers (Basel). https://doi.org/10.3390/cancers13081803CrossRefPubMed

Titel: Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies
verfasst von: Martin D. Hyrcza
Tanya R. Lindenmuth
Aaron Auerbach
Publikationsdatum: 16.03.2023
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 1/2023
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-023-01532-2

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Epstein-Barr Virus Detection and LMP-1 Expression in Thai Patients with Oral Squamous Cell Carcinoma

Biphenotypic Sinonasal Sarcoma with a Novel PAX3::FOXO6 Fusion: A Case Report and Review of the Literature

Top 10 Significant Spindled Head and Neck Lesions to Scrutinze

Frozen Section Evaluation for Surgical Margins in Laryngeal Squamous Cell Carcinoma: Is it a Reliable Method for Partial and Total Laryngectomies?

Does Malignant Transformation of Basal Cell Adenoma Occur?

Top 10 Clear Cell Head and Neck Lesions to Contemplate

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren